NCT04649112View on ClinicalTrials.gov

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

December 22, 2022

Study Completion Date

September 30, 2023

Conditions
CD19 Expressing MalignanciesHematologic Malignancy
Interventions
GENETIC

PBCAR19B

Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused

Trial Locations (7)

10032

Columbia University, New York

19107

Thomas Jefferson University, Philadelphia

33612

Moffitt Cancer Center, Tampa

85234

Banner MDA, Gilbert

91010

City of Hope, Duarte

02111

Tufts Medical Center, Boston

02903

Lifespan Cancer Institute at Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Precision BioSciences, Inc.

INDUSTRY

NCT04649112 - Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies | Biotech Hunter | Biotech Hunter